AMAG - アマッグ・ファ―マシュ―ティカルズ (AMAG Pharmaceuticals Inc.) アマッグ・ファ―マシュ―ティカルズ

 AMAGのチャート


 AMAGの企業情報

symbol AMAG
会社名 AMAG Pharmaceuticals Inc. (アマッグ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 エーエムエージー・ファマシューティカルズ(AMAG Pharmaceuticals Inc.)は製薬会社である。同社の事業は妊婦の健康、貧血管理及びがん支援ケアに焦点を当て、各状態の治療に使用するための製品の製造、開発と商品化及びサービスの提供である。製品は妊婦の健康、貧血管理、がん支援ケアに重点を置く。製品には、マケナ(ヒドロキシプロゲステロンカプロン酸注射液)、臍帯血レジストリー(CBR)で運営される臍帯血幹細胞と臍帯組織ユニットの収集、処理と保管に関連するサービスを含み、静脈内(IV)使用の製品であるFeraheme、MuGard Mucoadhesive Oral Wound Rinseに使用される。同社は妊婦の重度子癇前症の治療のためのポリクローナル抗体であるジゴキシン免疫ファブの開発に従事する。マケナは自発的早産の病歴を持つ妊娠女性の早産のリスクを軽減する薬物である。   アマッグ・ファ―マシュ―ティカルズは米国の製薬会社。特許技術を用いて、鉄欠乏性貧血治療薬、癌・心血管疾患の診断に使用される画像診断薬の開発・販売を行う。主要製品は米国食品医薬品局(FDA)より、承認された慢性腎疾患に伴う鉄欠乏性貧血治療剤Feraheme(一般名はferumoxytol)。   AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
本社所在地 1100 Winter Street Waltham MA 02451 USA
代表者氏名 Gino Santini ジノサンティーニ
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-498-3300
設立年月日 29891
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 762人
url www.amagpharma.com
nasdaq_url https://www.nasdaq.com/symbol/amag
adr_tso
EBITDA EBITDA(百万ドル) 295.65000
終値(lastsale) 21.98
時価総額(marketcap) 757712517.66
時価総額 時価総額(百万ドル) 777.01730
売上高 売上高(百万ドル) 575.72100
企業価値(EV) 企業価値(EV)(百万ドル) 1168.3813
当期純利益 当期純利益(百万ドル) -250.11700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AMAG Pharmaceuticals Inc. revenues decreased 2% to $263.6M. Net loss before extraordinary items increased 65% to $83.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest and dividend income decrease of 6% to $1.6M (income).

 AMAGのテクニカル分析


 AMAGのニュース

   ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - AMAG, SBPH, VAR, SINA, GARS  2020/10/06 03:07:00 Benzinga
NEW YORK , Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Covis Group S.à r.l. for $13.75 per share in cash. Visit our website to learn more about your legal rights and options: https://halpersadeh.com/actions/amag-pharmaceuticals-inc-stock-merger-covis/ . Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH ) concerning potential violations … Full story available on Benzinga.com
   SHAREHOLDER ALERT: WeissLaw LLP Investigates AMAG Pharmaceuticals, Inc.  2020/10/03 00:35:00 PR Newswire
NEW YORK, Oct. 2, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (NASDAQ: AMAG) in connection with the proposed acquisition of the Company…
   51 Biggest Movers From Yesterday  2020/10/02 08:57:27 Benzinga
Gainers Solid Biosciences Inc. (NASDAQ: SLDB ) shares climbed 70.4% to close at $3.46 on Thursday after the company announced the FDA has lifted the clinical hold placed on the Company's IGNITE DMD Phase I/II clinical trial. Enlivex Therapeutics Ltd. (NASDAQ: ENLV ) shares rose 48% to close at $8.79 after the company announced positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition. AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) surged 45.2% to close at $13.65 following a report suggesting Apollo's Covis said they are in talks to buy the company. American Equity Investment Life Holding Company (NYSE: AEL ) shares gained 44.1% to close at $31.68. American Equity yesterday named Graham Day to lead Eagle Life Insurance Company®, a subsidiary of American Equity. Gridsum Holding Inc. (NASDAQ: GSUM ) gained 39.7% to close at $1.69 after the company entered into definitive agreement for a going-private transaction. CBAK Energy Technology, Inc. (NASDAQ: CBAT ) climbed 25.7% to close at $2.54.
   Amag Pops 45% On Covis Takeover Nod  2020/10/02 06:33:09 Smarter Analyst
Shares of Amag Pharmaceuticals climbed 45.2% on Thursday after the company approved a takeover bid by Covis Pharma. The post Amag Pops 45% On Covis Takeover Nod appeared first on Smarter Analyst .
   AMAG Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of AMAG Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – AMAG  2020/10/01 18:12:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) to Covis Group S.à r.l. (“Covis”) for $13.75 per share in cash is fair to AMAG shareholders. On behalf of AMAG shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. If you are an AMAG shareholder and would
   EANS-News: AMAG Austria Metall AG: Solides 1. Halbjahr in schwierigem Umfeld  2020/07/30 05:00:42 APA OTS
Halbjahresergebnis
   EANS-Tip Announcement: AMAG Austria Metall AG / Half-year financial report according to art. 125 para. 1 Stock Exchange Act  2020/07/30 05:00:26 APA OTS
The company AMAG Austria Metall AG is declaring the following financial reports below:
   AMAG Pharmaceuticals : to Host Second Quarter FY 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020 | MarketScreener  2020/07/28 12:11:10 MarketScreener
WALTHAM, Mass., July 28, 2020 - AMAG Pharmaceuticals, Inc. today announced that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 before the U.S…. | July 28, 2020
   Palatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi®  2020/07/27 11:00:00 PR Newswire
CRANBURY, N.J., July 27, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today…
   Celsion among healthcare gainers; Aurinia Pharmaceuticals and BioNTech among losers  2020/07/23 15:04:53 Seeking Alpha
Gainers: Milestone Pharmaceuticals MIST +137%. CymaBay Therapeutics CBAY +34%. Entera Bio ENTX +31%. Celsion (NASDAQ:CLSN) +27%. AMAG Pharmaceuticals AMAG
   EANS-News: AMAG Austria Metall AG: Solides 1. Halbjahr in schwierigem Umfeld  2020/07/30 05:00:42 APA OTS
Halbjahresergebnis
   EANS-Tip Announcement: AMAG Austria Metall AG / Half-year financial report according to art. 125 para. 1 Stock Exchange Act  2020/07/30 05:00:26 APA OTS
The company AMAG Austria Metall AG is declaring the following financial reports below:
   AMAG Pharmaceuticals : to Host Second Quarter FY 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020 | MarketScreener  2020/07/28 12:11:10 MarketScreener
WALTHAM, Mass., July 28, 2020 - AMAG Pharmaceuticals, Inc. today announced that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 before the U.S…. | July 28, 2020
   Palatin Technologies Announces Mutual Termination of License Agreement with AMAG Pharmaceuticals for Vyleesi®  2020/07/27 11:00:00 PR Newswire
CRANBURY, N.J., July 27, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today…
   Celsion among healthcare gainers; Aurinia Pharmaceuticals and BioNTech among losers  2020/07/23 15:04:53 Seeking Alpha
Gainers: Milestone Pharmaceuticals MIST +137%. CymaBay Therapeutics CBAY +34%. Entera Bio ENTX +31%. Celsion (NASDAQ:CLSN) +27%. AMAG Pharmaceuticals AMAG

 関連キーワード  (医薬品 米国株 アマッグ・ファ―マシュ―ティカルズ AMAG AMAG Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)